Market Data graphic

Sciences biologiques

Vous êtes ici

Le secteur des sciences biologiques comprend des sociétés dont les activités concernent les produits biopharmaceutiques, la fabrication et la distribution médicale et les produits biologiques.

TransCanna Holdings Inc. est une société californienne de promotion de la marque, de transport et de distribution de cannabis, qui aide les cultivateurs et les fabricants de cannabis à se faire reconnaître par les utilisateurs finaux et les consommateurs.

Each Warrant entitles the holder thereof upon exercise, together with payment of the exercise price of $3.00 before the time of expiry subject to acceleration to acquire one common share.

Transcanna Holdings Inc. - Common Shares

Tree of Knowledge International Corp (TOKI) has three primary business segments: (1) Multidisciplinary specialty pain clinics with a focus on the treatment of chronic pain, including controlled applications of medical cannabis in Canada. Through an exclusive strategic alliance with Jack Nathan Medical Inc., the Company has access to one of the largest healthcare systems across Canada and Internationally for its education and research platform (currently over 1.5 million patient visits annually); (2) Development of formulated products for therapeutic purposes and natural health product alternatives at its manufacturing facility in Spokane.  The Company also has research agreements with multiple universities for medical cannabis research and development of new medical grade products; and (3) Distribution and sale of hemp-based cannabidiol (“CBD”) products in the United States, Canada, Europe, Brazil and China. The CBD product line contains EVR Premium Hemp Oil, which is an organically grown and non-GMO.

True Leaf Medicine International Ltd., through its wholly-owned subsidiary ‘True Leaf Pet’, has entered the $104.9 billion global pet care industry with a line of hemp-focused pet chews and supplements marketed through natural pet health and veterinary channels in Canada, the United States and Europe. The company has also filed an application under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer through its ‘True Leaf Medicine’ subsidiary. It has passed through the preliminary and enhanced screening process of Health Canada’s review and is currently in the 'review' stage.

Trulieve Cannabis Corp. - Subordinate Voting Shares

Trulieve est une société de «semences à vendre» intégrée verticalement et est la première et la plus grande société de marijuana médicale sous licence de l'État de Floride. Trulieve cultive et produit tous ses produits en interne et distribue ces produits dans les magasins de marque Trulieve (dispensaires) dans tout l’État de Floride, ainsi que directement auprès des patients via la livraison à domicile.

Investor Note: In addition to the 7,554,050 Subordinate Voting Shares that are listed and trading, there are 102,256,850 shares reserved for issuance pursuant to the conversion rights attached to the Super Voting Shares and Multiple Voting Shares that are issued and outstanding but not listed. The total number of issued  shares assuming all are converted into the listed class would be 109,810,900.

Trulieve Cannabis Corp. - Subordinate Voting Shares

The Company is a pharmaceutical company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The Company intends to do this through the development of compounds with known activity and/or safety profiles. The Company’s lead program is designed to address neurological disorders through the therapeutic dosing of synthetic psilocybin. The Company is currently evaluating potential lead indications for its psilocybin-for-neurology program, which it refers to as its PFN™ program, including fibromyalgia and Prader-Willi Syndrome. In addition to its PFN™ program, the Company is developing razoxane for the treatment of soft-tissue sarcomas. The Company continues to evaluate potential additional indications for its existing programs, as well as other drug candidates with known activity and/or safety profiles that may have utility in the treatment of rare diseases or other diseases with high unmet medical needs.

Valeo Pharma est une société pharmaceutique spécialisée dans l'approbation et le lancement de produits de prescription novateurs au Canada. Axé sur les maladies neurodégénératives, la santé de la femme et les maladies rares, Valeo Pharma dispose d’un portefeuille croissant de produits innovants et d’une plateforme lui permettant de gérer correctement ces produits à toutes les étapes de la commercialisation. Basée à Kirkland, au Québec, Valeo Pharma dispose de toutes les capacités internes pour enregistrer et commercialiser des solutions de soins de santé destinées aux patients canadiens. Pour plus d'informations, s'il vous plaît visitez www.valeopharma.com.

Valeo Pharma Inc. - Common Shares

Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada. With a focus on neurodegenerative diseases, woman’s health and oncology, Valeo Pharma has a growing portfolio of innovative products and the proper infrastructure to manage these products through all stages of commercialization.  Headquartered in Kirkland, Quebec, Valeo Pharma has all internal capabilities to register and market health care solutions for Canadian patients. For more information, please visit www.valeopharma.com

Advertisement

Publicité

Dernières nouvelles CSE

Évènements à venir

Advertisement

Publicité